⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8007195 | 0.78 | — | — | |
| SCHEMBL18804367 | 0.73 | — | — | |
| SCHEMBL24023402 | 0.73 | — | — | |
| SCHEMBL28612685 | 0.71 | — | — | |
| SCHEMBL18804267 | 0.69 | — | — | |
| SCHEMBL18804271 | 0.69 | — | — | |
| SCHEMBL21441962 | 0.69 | — | — | |
| SCHEMBL12976247 | 0.69 | — | — | |
| SCHEMBL12601477 | 0.67 | — | — | |
| SCHEMBL18804363 | 0.65 | ALDH1A1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718628-B2 | SREBP inhibitors comprising a 6-membered central ring | CAPULUS THERAPEUTICS, LLC (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230212170-A1 | INHIBITORS OF KRAS G12C PROTEIN AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-07-06 | — | — | US | disclosed |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230165095-A1 | LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-05-25 | — | — | US | disclosed |
| US-20230147053-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2023-05-11 | — | — | US | disclosed |
| US-11639346-B2 | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS | ARAXES PHARMA LLC (US) | 2023-05-02 | — | — | US | disclosed |
| US-20220402952-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-12-22 | — | — | US | disclosed |
| US-11377441-B2 | Covalent inhibitors of KRAS | ARAXES PHARMA LLC (US) | 2022-07-05 | — | — | US | disclosed |
| US-11279689-B2 | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer | ARAXES PHARMA LLC (US) | 2022-03-22 | — | — | US | disclosed |
| US-20210380595-A1 | 2-(2-ACRYLOYL-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-6-(1H-INDAZOL-4-YL)-BENZONITRILE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF G12C MUTANT KRAS PROTEIN FOR INHIBITING TUMOR METASTASIS | ARAXES PHARMA LLC (US) | 2021-12-09 | — | — | US | disclosed |
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170197945-A1 | 2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2017-07-13 | — | — | US | disclosed |
| US-20170197945-A1 | 2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2017-07-13 | — | — | US | disclosed |
| US-20170022184-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2017-01-26 | — | — | US | disclosed |
| US-20170022184-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2017-01-26 | — | — | US | disclosed |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
| US-20160108019-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2016-04-21 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |